Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers programs for the treatment of diamond-blackfan anemia, Bone Marrow Failure Syndromes, novel fetal hemoglobin inducers, fibrotic disorders. It has licensce agreement with CAMP4 which includes certain small molecule compounds, composition of matter and method of use patent rights, and know-how to research, develop, manufacture, use, and commercialize. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.…
Slate Medicines Starts Migraine Treatment Study
Fulcrum Therapeutics (NASDAQ: FULC) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 55 employees.
The shares were at 3.690 USD on 20 November 2026, down 51.6% over 52 weeks. Its 52-week range is 2.910 USD to 15.74 USD: the price is 76.6% below the high and 26.8% above the low.
Its market capitalisation is 281.85M USD.
Fulcrum Therapeutics reports return on equity of -21.5% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 299.72M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 3 analysts cover the stock, with an average rating of Hold; their mean price target of 3.667 USD is 0.6% below the current price. The next earnings report is expected on 24 February 2027.